search-icon
Loading...

Guidance 2024

In the current financial year (2024), the Managing Board expects continued fast sales growth as well as solid margins. In the mid- to long-term, an adj. EBITDA margin in excess of 8% is anticipated.

€ 2.3-2.5 Bn
Total net sales
30-40%
Total net sales growth
15-25%
Non-Rx sales growth
2-4%
Adjusted EBITDA margin